Provention Bio, Inc. stock price
Today's NASDAQ:PRVB chart, history & news
Price:
14.99
USD
Change:
-0.01 (-0.07%)
Key stats
| Price open | 15.66 |
|---|---|
| Previous close | 15 |
| Market cap | 846.75M |
| Volume | 1.51M |
| Day high | |
| Day low | |
| Year high | 19.45 |
| Year low | 5.42 |
| Year to date change | -11.58% |
| P/E ratio | N.A |
Company Profile
Fundamentals
Insider Information
News
Company information
Company name
Provention Bio, Inc.
Exchange
Sector
Manufacturing
Industry
Medicinal and Botanical Manufacturing
CEO
Ashleigh Palmer
Address
55 Broad Street, 2Nd Floor, Red bank, New jersey, 07701
Country
United States
Contact information
19084289136
Website
https://www.proventionbio.com/
Related companies
Provention Bio, Inc. earnings reports (2020)
| Q3 2020 | Q2 2020 | Q1 2020 | Q1 2020 | |
|---|---|---|---|---|
| Actual EPS | -0.56 | -0.45 | -0.26 | -0.26 |
| Consensus EPS | -0.427143 | -0.28 | -0.25 | -0.25 |
| Announce Time | BTO | BTO | AMC | AMC |
| Number of Estimates | 7 | 7 | 3 | 3 |
| EPS Surprise Dollar | -0.13285699486732 | -0.17 | -0.01 | -0.01 |
| EPS Report Date | 05-11-2020 | 06-08-2020 | 06-05-2020 | 06-05-2020 |
| Fiscal End Date | 30-09-2020 | 30-06-2020 | 30-03-2020 | 30-03-2020 |
| Year Ago | -0.24 | -0.32 | -0.29 | -0.29 |
| Year Ago % Change | 133.33333954215% | -40.63% | 10.34% | 10.34% |
Provention Bio, Inc. earnings reports (2019)
| Q4 2019 | Q3 2019 | Q2 2019 | |
|---|---|---|---|
| Actual EPS | -0.22 | -0.24 | -0.32 |
| Consensus EPS | -0.24 | -0.29 | -0.31 |
| Announce Time | BTO | AMC | BTO |
| Number of Estimates | 3 | 3 | 3 |
| EPS Surprise Dollar | 0.02 | 0.05 | -0.01 |
| EPS Report Date | 12-03-2020 | 05-11-2019 | 05-08-2019 |
| Fiscal End Date | 31-12-2019 | 29-09-2019 | 29-06-2019 |
| Year Ago | -0.15 | -0.2 | N.A |
| Year Ago % Change | -46.67% | -20% | N.A |
Provention Bio, Inc. income statements (2020) (USD)
| June 2020 | June 2020 | March 2020 | March 2020 | |
|---|---|---|---|---|
| Total Revenue | N.A | N.A | N.A | N.A |
| Cost of Revenue | N.A | N.A | N.A | N.A |
| Gross Profit | N.A | N.A | N.A | N.A |
| Research & Development | 15.03M | 15.03M | 9.09M | 9.09M |
| Selling General & Admin | 7.76M | 7.76M | 3.78M | 3.78M |
| Operating Expense | 22.80M | 22.80M | 12.87M | 12.87M |
| Operating Income | -22.8M | -22.8M | -12.87M | -12.87M |
| Other Income Expense Net | 151K | 151K | 283K | 283K |
| EBIT | -22.8M | -22.8M | -12.87M | -12.87M |
| Interest Income | N.A | N.A | N.A | N.A |
| Pretax Income | -22.65M | -22.65M | -12.58M | -12.58M |
| Income Tax | -523K | -523K | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -22.12M | -22.12M | -12.58M | -12.58M |
| Net Income Basic | -22.12M | -22.12M | -12.58M | -12.58M |
Provention Bio, Inc. income statements (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Total Revenue | N.A | N.A | N.A | N.A |
| Cost of Revenue | N.A | N.A | N.A | N.A |
| Gross Profit | N.A | N.A | N.A | N.A |
| Research & Development | 8.46M | 7.32M | 10.55M | 10.02M |
| Selling General & Admin | 2.42M | 2.65M | 1.71M | 1.24M |
| Operating Expense | 10.88M | 9.97M | 12.26M | 11.26M |
| Operating Income | -10.88M | -9.97M | -12.26M | -11.26M |
| Other Income Expense Net | 343K | 204K | 253K | 287K |
| EBIT | -10.88M | -9.97M | -12.26M | -11.26M |
| Interest Income | N.A | N.A | N.A | N.A |
| Pretax Income | -10.54M | -9.77M | -12M | -10.97M |
| Income Tax | N.A | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -10.54M | -9.77M | -12M | -10.97M |
| Net Income Basic | -10.54M | -9.77M | -12M | -10.97M |
Provention Bio, Inc. income statements (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Total Revenue | N.A | N.A | N.A | N.A |
| Cost of Revenue | N.A | N.A | N.A | N.A |
| Gross Profit | N.A | N.A | N.A | N.A |
| Research & Development | 4.97M | 4.14M | 9.16M | 4.38M |
| Selling General & Admin | 1.24M | 1.27M | 1M | 653.26K |
| Operating Expense | 6.20M | 5.41M | 10.17M | 5.04M |
| Operating Income | -6.2M | -5.41M | -10.17M | -5.04M |
| Other Income Expense Net | 330K | 20K | -174K | -27.42K |
| EBIT | -6.2M | -5.41M | -10.17M | -5.04M |
| Interest Income | N.A | N.A | N.A | N.A |
| Pretax Income | -5.87M | -5.39M | -10.34M | -5.06M |
| Income Tax | -187K | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -5.68M | -5.39M | -10.34M | -5.06M |
| Net Income Basic | -5.68M | -5.42M | -10.47M | -5.19M |
Provention Bio, Inc. income statements (2017) (USD)
| December 2017 | |
|---|---|
| Total Revenue | N.A |
| Cost of Revenue | N.A |
| Gross Profit | N.A |
| Research & Development | 3.07M |
| Selling General & Admin | 668.66K |
| Operating Expense | 3.73M |
| Operating Income | -3.73M |
| Other Income Expense Net | 49.50K |
| EBIT | -3.73M |
| Interest Income | N.A |
| Pretax Income | -3.68M |
| Income Tax | N.A |
| Minority Interest | 0 |
| Net Income | -3.68M |
| Net Income Basic | -3.81M |
Provention Bio, Inc. balance sheet (2020) (USD)
| June 2020 | March 2020 | March 2020 | |
|---|---|---|---|
| Current Cash | 145.89M | 37.14M | 37.14M |
| Receivables | N.A | N.A | N.A |
| Inventory | N.A | N.A | N.A |
| Current Assets | 175.76M | 78.12M | 78.12M |
| Other Current Assets | 3.60M | 1.49M | 1.49M |
| Short Term Investments | 26.27M | 39.49M | 39.49M |
| Long Term Investments | N.A | N.A | N.A |
| Property/Plant Equipment | N.A | N.A | N.A |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | N.A | N.A | N.A |
| Tangible Assets (Net) | 163.78M | 71.21M | 71.21M |
| Other Assets | N.A | N.A | N.A |
| Total Assets | 175.76M | 78.12M | 78.12M |
| Accounts Payable | 7.83M | 3.54M | 3.54M |
| Other Current Liabilities | 4.15M | 3.37M | 3.37M |
| Total Current Liabilities | 11.98M | 6.90M | 6.90M |
| Total Liabilities | 11.98M | 6.90M | 6.90M |
| Long Term Debt | N.A | N.A | N.A |
| Current Long Term Debt | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 |
| Common Stock | 56.22M | 47.71M | 47.71M |
| Treasury Stock | N.A | N.A | N.A |
| Retained Earnings | -113.77M | -91.64M | -91.64M |
| Capital Surplus | 277.44M | 162.64M | 162.64M |
| Shareholder Equity | 163.78M | 71.21M | 71.21M |
| Other Liabilities | N.A | N.A | N.A |
Provention Bio, Inc. balance sheet (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Current Cash | 39.17M | 95.09M | 41.26M | 51.21M |
| Receivables | N.A | N.A | N.A | N.A |
| Inventory | N.A | N.A | N.A | N.A |
| Current Assets | 86M | 96.37M | 42.45M | 51.90M |
| Other Current Assets | 623K | 1.28M | 1.19M | 698K |
| Short Term Investments | 46.21M | N.A | N.A | N.A |
| Long Term Investments | N.A | N.A | N.A | N.A |
| Property/Plant Equipment | N.A | N.A | N.A | N.A |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | N.A | N.A | N.A | N.A |
| Tangible Assets (Net) | 82.16M | 91.41M | 37.41M | 48.93M |
| Other Assets | N.A | N.A | N.A | N.A |
| Total Assets | 86M | 96.37M | 42.45M | 51.90M |
| Accounts Payable | 1.78M | 2.27M | 3.80M | 779K |
| Other Current Liabilities | 2.07M | 2.70M | 1.24M | 2.20M |
| Total Current Liabilities | 3.84M | 4.96M | 5.04M | 2.97M |
| Total Liabilities | 3.84M | 4.96M | 5.04M | 2.97M |
| Long Term Debt | N.A | N.A | N.A | N.A |
| Current Long Term Debt | N.A | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 47.66M | 47.64M | 37.37M | 37.36M |
| Treasury Stock | N.A | N.A | N.A | N.A |
| Retained Earnings | -79.06M | -68.52M | -58.75M | -46.75M |
| Capital Surplus | 161.21M | 159.93M | 96.16M | 95.67M |
| Shareholder Equity | 82.16M | 91.41M | 37.41M | 48.93M |
| Other Liabilities | N.A | N.A | N.A | N.A |
Provention Bio, Inc. balance sheet (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Current Cash | 58.54M | 64.30M | N.A | 15.85M |
| Receivables | N.A | N.A | N.A | N.A |
| Inventory | N.A | N.A | N.A | N.A |
| Current Assets | 61.53M | 66.32M | 12.24M | 18.09M |
| Other Current Assets | 2.99M | 2.03M | 2.03M | 2.24M |
| Short Term Investments | N.A | N.A | N.A | N.A |
| Long Term Investments | N.A | N.A | N.A | N.A |
| Property/Plant Equipment | N.A | N.A | N.A | N.A |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | N.A | N.A | N.A | N.A |
| Tangible Assets (Net) | 59.66M | 65.09M | 9.24M | 15.19M |
| Other Assets | N.A | N.A | N.A | N.A |
| Total Assets | 61.53M | 66.32M | 12.24M | 18.09M |
| Accounts Payable | N.A | 524K | N.A | N.A |
| Other Current Liabilities | 1.87M | 710K | 1.69M | 1.82M |
| Total Current Liabilities | 1.87M | 1.23M | 1.69M | 1.82M |
| Total Liabilities | 1.87M | 1.23M | 2.99M | 2.90M |
| Long Term Debt | N.A | N.A | N.A | N.A |
| Current Long Term Debt | N.A | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 37.36M | 37.35M | 37.35M | 36.38M |
| Treasury Stock | N.A | N.A | N.A | N.A |
| Retained Earnings | -35.78M | -30.09M | -24.7M | -14.36M |
| Capital Surplus | 95.43M | 95.18M | 7.51M | 3.24M |
| Shareholder Equity | 59.66M | 65.09M | 9.24M | 15.19M |
| Other Liabilities | N.A | N.A | N.A | N.A |
Provention Bio, Inc. balance sheet (2017) (USD)
| December 2017 | |
|---|---|
| Current Cash | 21.83M |
| Receivables | N.A |
| Inventory | N.A |
| Current Assets | 22.43M |
| Other Current Assets | 594.21K |
| Short Term Investments | N.A |
| Long Term Investments | N.A |
| Property/Plant Equipment | N.A |
| Good Will | N.A |
| Intangible Assets | N.A |
| Tangible Assets (Net) | 20.15M |
| Other Assets | N.A |
| Total Assets | 22.43M |
| Accounts Payable | N.A |
| Other Current Liabilities | 1.28M |
| Total Current Liabilities | 1.28M |
| Total Liabilities | 2.28M |
| Long Term Debt | N.A |
| Current Long Term Debt | N.A |
| Minority Interest | 0 |
| Common Stock | 36.38M |
| Treasury Stock | N.A |
| Retained Earnings | -9.3M |
| Capital Surplus | 3.26M |
| Shareholder Equity | 20.15M |
| Other Liabilities | N.A |
Provention Bio, Inc. cash flow (2020) (USD)
| June 2020 | March 2020 | |
|---|---|---|
| Net Income | -22.12M | -12.58M |
| Depreciation | N.A | N.A |
| Changes in Receivables | N.A | N.A |
| Changes in Inventories | N.A | N.A |
| Cash Change | 108.75M | -2.02M |
| Cash Flow | -17.77M | -9.17M |
| Capital Expenditures | N.A | N.A |
| Investments | 13M | 6.95M |
| Investing Activity (other) | N.A | N.A |
| Total Investing Cash Flows | 13M | 6.95M |
| Dividends Paid | N.A | N.A |
| Net Borrowings | N.A | N.A |
| Other Financing Cash Flows | N.A | N.A |
| Cash Flow Financing | 113.52M | 194K |
| Exchange Rate Effect | N.A | N.A |
Provention Bio, Inc. cash flow (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Net Income | -10.54M | -9.77M | -12M | -10.97M |
| Depreciation | N.A | N.A | N.A | N.A |
| Changes in Receivables | N.A | N.A | N.A | N.A |
| Changes in Inventories | N.A | N.A | N.A | N.A |
| Cash Change | -55.92M | 53.83M | -9.95M | -7.33M |
| Cash Flow | -9.74M | -9.02M | -9.97M | -7.33M |
| Capital Expenditures | N.A | N.A | N.A | N.A |
| Investments | -46.25M | N.A | N.A | N.A |
| Investing Activity (other) | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | -46.25M | N.A | N.A | N.A |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | N.A | N.A | N.A | N.A |
| Other Financing Cash Flows | N.A | N.A | N.A | N.A |
| Cash Flow Financing | 71K | 62.85M | 21K | N.A |
| Exchange Rate Effect | N.A | N.A | N.A | N.A |
Provention Bio, Inc. cash flow (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Net Income | -5.68M | -5.39M | -10.34M | -5.06M |
| Depreciation | N.A | N.A | N.A | N.A |
| Changes in Receivables | N.A | N.A | N.A | N.A |
| Changes in Inventories | N.A | N.A | N.A | N.A |
| Cash Change | -5.76M | 54.09M | -5.64M | -5.99M |
| Cash Flow | -5.78M | -5.92M | -4.96M | -5.99M |
| Capital Expenditures | N.A | N.A | N.A | N.A |
| Investments | N.A | N.A | N.A | N.A |
| Investing Activity (other) | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | N.A | N.A | N.A | N.A |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | N.A | N.A | N.A | N.A |
| Other Financing Cash Flows | N.A | N.A | N.A | N.A |
| Cash Flow Financing | 20K | 60.01M | -681K | N.A |
| Exchange Rate Effect | N.A | N.A | N.A | N.A |
Provention Bio, Inc. dividends (USD)
Insider Roster
| Entity name | Report date | Shares held |
|---|---|---|
| Ramos Eleanor | 02-09-2020 | 64,799 |
| Leon Francisco | 21-08-2020 | 2,567,450 |
| Palmer Ashleigh | 18-08-2020 | 2,566,300 |
| Jenkins John Kenneth | 11-08-2020 | 128,981 |
| King-Jones Heidy | 03-08-2020 | 300,000 |
| Hoitt Jason | 16-07-2020 | 137,750 |
| Bluestone Jeffrey | 16-07-2020 | 22,200 |
| CATLIN AVERY W | 16-07-2020 | 22,200 |
| Doherty Sean M | 16-07-2020 | 22,200 |
| DIGIANDOMENICO ANTHONY | 06-12-2019 | 520,712 |
Insider Summary
| Full name | Reported title | Total bought | Total sold | Net transacted |
|---|---|---|---|---|
| King-Jones Heidy | Chief Legal Officer | 600,000 | 0 | 600,000 |
Insider Transactions
| Full name | Reported title | Effective date | Amount of shares | Price per share | Total cost |
|---|---|---|---|---|---|
| Ramos Eleanor | Chief Medical Officer | 02-09-2020 | +299 | 12.06 | +3,605.94 |
| Drechsler Andrew T | Chief Financial Officer | 02-09-2020 | +2,000 | 11.72 | +23,440.00 |
| Leon Francisco | Chief Scientific Officer | 21-08-2020 | +2,000 | 13.35 | +26,708.00 |
| Ramos Eleanor | Chief Medical Officer | 20-08-2020 | +2,500 | 13.23 | +33,075.00 |
| Palmer Ashleigh | President and CEO | 18-08-2020 | +500 | 12.69 | +6,345.00 |
| Palmer Ashleigh | President and CEO | 17-08-2020 | +2,800 | 12.83 | +35,924.00 |
| Drechsler Andrew T | Chief Financial Officer | 13-08-2020 | +1,750 | 13.01 | +22,767.50 |
| Jenkins John Kenneth | 10-08-2020 | +128,981 | N.A | N.A | |
| King-Jones Heidy | Chief Legal Officer | 03-08-2020 | +300,000 | N.A | N.A |
| Hoitt Jason | Chief Commercial Officer | 15-07-2020 | +137,750 | N.A | N.A |
| CATLIN AVERY W | 15-07-2020 | +22,200 | N.A | N.A | |
| Palmer Ashleigh | President and CEO | 15-07-2020 | +137,750 | N.A | N.A |
| Ramos Eleanor | Chief Medical Officer | 15-07-2020 | +137,750 | N.A | N.A |
| Drechsler Andrew T | Chief Financial Officer | 15-07-2020 | +137,750 | N.A | N.A |
| Leon Francisco | Chief Scientific Officer | 15-07-2020 | +137,750 | N.A | N.A |
| Pisano Wayne | 15-07-2020 | +22,200 | N.A | N.A | |
| Doherty Sean M | 15-07-2020 | +22,200 | N.A | N.A | |
| Wysenski Nancy | 15-07-2020 | +22,200 | N.A | N.A | |
| Bluestone Jeffrey | 15-07-2020 | +22,200 | N.A | N.A | |
| Leon Francisco | Chief Scientific Officer | 24-06-2020 | +2,000 | 15.43 | +30,862.00 |
| Wysenski Nancy | 19-05-2020 | +128,981 | N.A | N.A | |
| Bluestone Jeffrey | 10-04-2020 | +32,246 | N.A | N.A | |
| Bluestone Jeffrey | 27-02-2020 | -24,000 | N.A | N.A | |
| Eleanor Leni Ramos | CMO & COO | 26-12-2019 | +2,000 | 14.34 | +28,680.00 |
| Ashleigh W. Palmer | President and CEO; Director | 20-12-2019 | +2,075 | 11.39 | +23,634.25 |
| Francisco Leon | Chief Scientific Officer | 16-12-2019 | +2,000 | 11.92 | +23,840.00 |
| Anthony DiGiandomenico | Director | 03-12-2019 | +342,000 | N.A | N.A |
| Francisco Leon | Chief Scientific Officer | 30-09-2019 | +1,450 | 7.67 | +11,121.50 |
| Anthony DiGiandomenico | Director | 30-09-2019 | +30,000 | 6.83 | +204,900.00 |
| Sean Doherty | Director | 26-09-2019 | +128,981 | N.A | N.A |
| Anthony DiGiandomenico | Director | 26-09-2019 | +5,000 | 8.44 | +42,200.00 |
| Anthony DiGiandomenico | Director | 25-09-2019 | +5,000 | 8.39 | +41,950.00 |
| Ashleigh W. Palmer | President and CEO; Director | 24-09-2019 | +3,000 | 8.38 | +25,140.00 |
| Francisco Leon | Chief Scientific Officer | 08-08-2019 | +2,500 | 9.09 | +22,725.00 |
| Ashleigh W. Palmer | President and CEO; Director | 08-08-2019 | +10,600 | 9.15 | +96,990.00 |
| Anthony DiGiandomenico | Director | 08-08-2019 | +10,000 | 9.09 | +90,900.00 |
| Jeffrey A. Bluestone | Director | 24-06-2019 | +24,000 | N.A | N.A |
| Francisco Leon | Chief Scientific Officer | 24-06-2019 | +400,000 | N.A | N.A |
| Ashleigh W. Palmer | President & CEO; Director | 24-06-2019 | +400,000 | N.A | N.A |
| Wayne F. Pisano | Director | 24-06-2019 | +24,000 | N.A | N.A |
| Andrew T. Drechsler | Chief Financial Officer | 24-06-2019 | +400,000 | N.A | N.A |
| Avery W. Catlin | Director | 24-06-2019 | +24,000 | N.A | N.A |
| Eleanor Leni Ramos | Chief Medical Officer and COO | 24-06-2019 | +400,000 | N.A | N.A |
| Anthony DiGiandomenico | Director | 24-06-2019 | +24,000 | N.A | N.A |
| Anthony DiGiandomenico | Director | 20-06-2019 | +10,000 | 10.96 | +109,600.00 |
| Ashleigh W. Palmer | President and CEO; Director | 18-06-2019 | +4,000 | 10.83 | +43,320.00 |
| Anthony DiGiandomenico | Director | 18-06-2019 | +10,000 | 10.88 | +108,800.00 |
| Jeffrey A. Bluestone | Director | 17-06-2019 | -7,300 | 11.93 | 87,089.00 |
| Anthony DiGiandomenico | Director | 17-06-2019 | +25,000 | 12.16 | +304,000.00 |